Nadroparin

Active bleeding or increased risk of haemorrhage related to haemostasis disorders (except disseminated intravascular coagulation not heparin-induced); haemorrhagic CVA, organic lesions likely to bleed (e.g. active peptic ulcer), history of thrombocytopenia with nadroparin; acute infectious endocarditis. Severe renal impairment (CrCl <30 mL/min) when used for the treatment of thromboembolic disorders, unstable angina, and non-Q wave MI.

Patient with severe arterial hypertension, history of gastrointestinal ulceration, vascular disorder of chorio-retina, hepatic failure, risk factors for hyperkalaemia (e.g. diabetes mellitus, metabolic acidosis, haematoma in body tissues, use of ACE inhibitors, NSAIDs, K-sparing diuretics or K supplements). Patients who are undergoing knee surgery, spinal puncture, or receiving neuraxial anaesthesia (spinal or epidural anaesthesia); postoperative period after brain, spinal cord or eye surgery. Not interchangeable (unit for unit) with any other LMWHs or heparin. Not intended for IM administration. Hepatic and moderate renal (CrCl ≥30 to <50 mL/min) impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor platelet count at baseline and twice weekly during treatment; antifactory Xa levels at least 4 hours postdose as clinically indicated; stool occult blood tests, Hb, LFT, renal function; plasma K levels in patients at risk of hyperkalaemia. Closely monitor for signs and symptoms of bleeding, thrombocytopenia with thrombosis and neurological impairment, and clotting in the dialysis circuit (when used during haemodialysis).

Significant: Haemorrhage at any site, thrombocytopenia with thrombosis, heparin-induced thrombocytopenia, hyperkalaemia, prosthetic valve thrombosis; epidural or spinal haematomas including subsequent chronic or permanent paralysis (in patients receiving neuraxial anaesthesia or undergoing spinal puncture). Rarely, cutaneous necrosis (preceded by purpura, infiltrated or painful erythematous blotches). Blood and lymphatic system disorders: Rarely, eosinophilia (reversible). General disorders and administration site conditions: Inj site haematoma and reaction. Immune system disorders: Rarely, hypersensitivity reactions. Investigations: Increased transaminases (transient). Nervous system disorders: Headache, migraine. Reproductive system and breast disorders: Rarely, priapism. Skin and subcutaneous tissue disorders: Rarely, rash, erythema, urticaria, pruritus.

Increased risk of bleeding with aspirin, antiplatelet agents and NSAIDs. May enhance the hyperkalaemic effect of ACE inhibitors and K-sparing diuretics.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB06 - nadroparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.